Links dos trabalhados publicados pelo grupo da Fundação Bahiana de Infectologia no IAS 2026.
Favorable tolerability of lenacapavir for PrEP administered at participant-chosen anatomic sites in PURPOSE 1 and PURPOSE 2 – https://programme.aids2026.org/Abstract/Abstract/?abstractid=5101
Biological and psychosocial factors in cognitive impairment among older adults with HIV: a cross-sectional evaluation from ELEA-Brasil study – https://programme.aids2026.org/Abstract/Abstract/?abstractid=4305
Sex-specific signature of short-chain fatty acid deficiency in aging men and women with HIV and CVD in Brazil – https://programme.aids2026.org/Abstract/Abstract/?abstractid=5150
Incidence and outcomes of AIDS-defining illnesses after dolutegravir/lamivudine initiation in advanced HIV in the DOLCE study – https://programme.aids2026.org/Abstract/Abstract/?abstractid=7743
Pharmacotherapy profile of older people living with HIV in three Brazilian cities: the role of complexity of pharmacotherapy in medication adherence – https://programme.aids2026.org/Abstract/Abstract/?abstractid=8001
Plasma inflammatory biomarkers and cognitive performance among older adults living with HIV – https://programme.aids2026.org/Abstract/Abstract/?abstractid=9385
Frequency and type of adverse events death in people with HIV treated with dolutegravir or comparator drugs in the CODE cohort, Brazil – https://programme.aids2026.org/Abstract/Abstract/?abstractid=10466
Body weight and BMI changes associated with DTG treatment in Brazil: results from CODE, a country-wide cohort study – https://programme.aids2026.org/Abstract/Abstract/?abstractid=10796
Viral suppression associated with DTG treatment in Brazil: results from CODE, a country-wide cohort study – https://programme.aids2026.org/Abstract/Abstract/?abstractid=11092